350 related articles for article (PubMed ID: 27096622)
1. Challenges and opportunities in treating inflammation associated with pulmonary hypertension.
Voelkel NF; Tamosiuniene R; Nicolls MR
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):939-51. PubMed ID: 27096622
[TBL] [Abstract][Full Text] [Related]
2. Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective.
Wang RR; Yuan TY; Wang JM; Chen YC; Zhao JL; Li MT; Fang LH; Du GH
Pharmacol Res; 2022 Jun; 180():106238. PubMed ID: 35504356
[TBL] [Abstract][Full Text] [Related]
3. Leptin signalling system as a target for pulmonary arterial hypertension therapy.
Huertas A; Tu L; Thuillet R; Le Hiress M; Phan C; Ricard N; Nadaud S; Fadel E; Humbert M; Guignabert C
Eur Respir J; 2015 Apr; 45(4):1066-80. PubMed ID: 25745038
[TBL] [Abstract][Full Text] [Related]
4. Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.
Liang S; Desai AA; Black SM; Tang H
Adv Exp Med Biol; 2021; 1303():275-303. PubMed ID: 33788198
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory and immunosuppressive agents in PAH.
Meloche J; Renard S; Provencher S; Bonnet S
Handb Exp Pharmacol; 2013; 218():437-76. PubMed ID: 24092351
[TBL] [Abstract][Full Text] [Related]
6. Inflammation in pulmonary arterial hypertension.
Price LC; Wort SJ; Perros F; Dorfmüller P; Huertas A; Montani D; Cohen-Kaminsky S; Humbert M
Chest; 2012 Jan; 141(1):210-221. PubMed ID: 22215829
[TBL] [Abstract][Full Text] [Related]
7. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension.
Kherbeck N; Tamby MC; Bussone G; Dib H; Perros F; Humbert M; Mouthon L
Clin Rev Allergy Immunol; 2013 Feb; 44(1):31-8. PubMed ID: 21394427
[TBL] [Abstract][Full Text] [Related]
8. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension.
Hashimoto-Kataoka T; Hosen N; Sonobe T; Arita Y; Yasui T; Masaki T; Minami M; Inagaki T; Miyagawa S; Sawa Y; Murakami M; Kumanogoh A; Yamauchi-Takihara K; Okumura M; Kishimoto T; Komuro I; Shirai M; Sakata Y; Nakaoka Y
Proc Natl Acad Sci U S A; 2015 May; 112(20):E2677-86. PubMed ID: 25941359
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of vascular endothelial growth factor receptor under hypoxia causes severe, human-like pulmonary arterial hypertension in mice: potential roles of interleukin-6 and endothelin.
Van Hung T; Emoto N; Vignon-Zellweger N; Nakayama K; Yagi K; Suzuki Y; Hirata K
Life Sci; 2014 Nov; 118(2):313-28. PubMed ID: 24412382
[TBL] [Abstract][Full Text] [Related]
11. Pathology of pulmonary hypertension.
Tuder RM; Stacher E; Robinson J; Kumar R; Graham BB
Clin Chest Med; 2013 Dec; 34(4):639-50. PubMed ID: 24267295
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary arterial hypertension (PAH) from autopsy study: T-cells, B-cells and mastocytes detection as morphological evidence of immunologically mediated pathogenesis.
Mansueto G; Di Napoli M; Campobasso CP; Slevin M
Pathol Res Pract; 2021 Sep; 225():153552. PubMed ID: 34352438
[TBL] [Abstract][Full Text] [Related]
13. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.
Savai R; Pullamsetti SS; Kolbe J; Bieniek E; Voswinckel R; Fink L; Scheed A; Ritter C; Dahal BK; Vater A; Klussmann S; Ghofrani HA; Weissmann N; Klepetko W; Banat GA; Seeger W; Grimminger F; Schermuly RT
Am J Respir Crit Care Med; 2012 Nov; 186(9):897-908. PubMed ID: 22955318
[TBL] [Abstract][Full Text] [Related]
14. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary arterial hypertension and microRNAs--an ever-growing partnership.
Wang Y; Xue XY; Liu YX; Wang KF; Zang XF; Wang J; Wang PL; Zhang J; Pan L; Zhang SY; Wang JX
Arch Med Res; 2013 Oct; 44(7):483-7. PubMed ID: 24051036
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.
Rabinovitch M; Guignabert C; Humbert M; Nicolls MR
Circ Res; 2014 Jun; 115(1):165-75. PubMed ID: 24951765
[TBL] [Abstract][Full Text] [Related]
17. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans.
Paulin R; Dromparis P; Sutendra G; Gurtu V; Zervopoulos S; Bowers L; Haromy A; Webster L; Provencher S; Bonnet S; Michelakis ED
Cell Metab; 2014 Nov; 20(5):827-839. PubMed ID: 25284742
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension.
de Mendonça L; Felix NS; Blanco NG; Da Silva JS; Ferreira TP; Abreu SC; Cruz FF; Rocha N; Silva PM; Martins V; Capelozzi VL; Zapata-Sudo G; Rocco PRM; Silva PL
Stem Cell Res Ther; 2017 Oct; 8(1):220. PubMed ID: 28974252
[TBL] [Abstract][Full Text] [Related]
19. Human γ-herpesviruses Epstein-Barr virus and human herpesvirus-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension.
Valmary S; Dorfmüller P; Montani D; Humbert M; Brousset P; Degano B
Chest; 2011 Jun; 139(6):1310-1316. PubMed ID: 21051388
[TBL] [Abstract][Full Text] [Related]
20. Echocardiography in pediatric pulmonary arterial hypertension: early study on assessing disease severity and predicting outcome.
Ploegstra MJ; Roofthooft MT; Douwes JM; Bartelds B; Elzenga NJ; van de Weerd D; Hillege HL; Berger RM
Circ Cardiovasc Imaging; 2015 Jan; 8(1):. PubMed ID: 25552488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
